Skip to main content
SpringerLink
Log in

Important to consider HR-QOL when treating patients with RA

  • Drug economics and quality of life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nichol MB, Harada ASM. Measuring the effects of medication use on health-related quality of life in patients with rheumatoid arthritis: a review. Pharmacoeconomics 1999 Nov; 16 (5 Pt 1): 433–48

    Article  PubMed  CAS  Google Scholar 

  2. Scaling methods. Available from: http://web.hku.hk/-hrnwick/swresearch/scaling.htm [Accessed 2000 Oct 10]

  3. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997; 36 (5): 551–9

    Article  PubMed  CAS  Google Scholar 

  4. Liang MH, Larson MG, Cullen KE, et al. Comparative measurement efficacy and sensitivity of 5 health status instruments for arthritis research. Arthritis Rheum 1985; 28: 542–7

    Article  PubMed  CAS  Google Scholar 

  5. Fries JF. Quality-of-life considerations with respect to arthritis and nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104 (3A): 14S–2205

    Article  PubMed  CAS  Google Scholar 

  6. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheumatism 1998; 41 (5): 778–99

    Article  PubMed  CAS  Google Scholar 

  7. Bendtsen P, Åkerlind I, Hörnquist J. Pharmacological intervention in older patients with rheumatoid arthritis: quality of life aspects. Drugs Aging 1995; 7 (5): 338–46

    Article  PubMed  CAS  Google Scholar 

  8. Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6 (6): 513–22

    Article  PubMed  CAS  Google Scholar 

  9. Bendtsen P, Åkerlind I, Hörnquist JO. Assessment of quality of life in rheumatoid arthritis: methods and implications. Pharmacoeconomics 1994; 5 (4): 286–98

    Article  PubMed  CAS  Google Scholar 

  10. Alarcon GS. Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 1995; 21 (2): 589–604

    PubMed  CAS  Google Scholar 

  11. Ganz PA. Methods of assessing the effect of drug therapy on quality of life. Drug Saf 1990; 5 (4): 233–42

    Article  PubMed  CAS  Google Scholar 

  12. Fries JF. The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index. Control Clin Trials 1991; 12 (4 Suppl.): 106S–17S

    Article  PubMed  CAS  Google Scholar 

  13. Scott DL, Shipley M, Dawson A, et al. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. Br J Rheumatol 1998; 37: 546–54

    Article  PubMed  CAS  Google Scholar 

  14. Group for the Respect of Ethics and Excellence in Science (GREES): Rheumatoid Arthritis Section. Recommendation for the registration of drugs used in the treatment of rheumatoid arthritis. Br J Rheumatol 1998; 37: 211–5

    Article  Google Scholar 

  15. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. Arthritis Rheum 1992; 35: 1117–25

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Important to consider HR-QOL when treating patients with RA. Drugs Ther. Perspect 16, 12–16 (2000). https://doi.org/10.2165/00042310-200016110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200016110-00005

Keywords

Search

Navigation